— Marks the first novel psilocybin analog to enter clinical development — — Patient recruitment to commence immediately — — Pharmacokinetic and safety data readout expected in Q4 2022 — TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company...